NMIBC
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
ImmunityBioSAN DIEGO, CA
2 programs1
Intravesical Recombinant MycobacteriumPhase 1/21 trial
rMBCGN/A1 trial
Active Trials
NCT06810141Available
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
ImmunityBioIntravesical Recombinant Mycobacterium
ProkariumZH9
Clinical Trials (3)
Total enrollment: 62 patients across 3 trials
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
Start: May 2025Est. completion: Feb 202840 patients
Phase 1/2Not Yet Recruiting
A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer
Start: Jan 2024Est. completion: Jul 202722 patients
Phase 1Active Not Recruiting
ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
N/AAvailable
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space